Thiazolidinediones, a class of oral insulin sensitizing agents that improve insulin resistance, are agonists of peroxisome
proliferator activated receptor-ϒ (PPAR-ϒ). Two clinically used drugs pioglitazone (ACTOS) and rosiglitazone (AVANDIA)
have made a great contribution to therapy for type 2 diabetes. However, weight gain and hepatotoxicity are side effects of
thiazolidinediones. For thiazolidinediones with lesser side effects, researchers are focusing on modification of side chain at
C-5 of thiazolidinedione nucleus and its derivatization. Netoglitazone possesses both PPAR-⍺/ϒ dual agonistic activity.
More thiazolidinedione derivatives like DRF-2189, PHT46, PMT13, DRF-2519 can be utilized as potent antidiabetic agents
in future.

Disclaimer: NISCAIR assumes no responsibility for the statements and opinions advanced by contributors. The editorial staff in its work of examining papers received for publication is helped, in an honorary capacity, by many distinguished engineers and scientists.